Trial Profile
A Randomized Clinical Trial of Dimethyl Fumarate as a Novel Therapeutic Agent for Obstructive Sleep Apnea
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- 27 Dec 2016 Status changed from active, no longer recruiting to completed.
- 08 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 May 2015 New trial record